BOSTON, February 04, 2025--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target Astria is using its half-life extension technology to ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS). Jonathan Wolleben’s rating is based on Astria Therapeutics’ innovative approach ...

BOSTON, February 03, 2025--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases ...

On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that ...

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that ...

M42, the Abu Dhabi-based AI-powered global health leader, announced partnering with Rhapsody, a leading digital health enablement platform, to empower precision medicine initiatives across the UAE and ...

DUBAI - Global health leader M42, which is powered by artificial intelligence (AI) and technology, has announced a groundbreaking partnership with Rhapsody, a leading digital health enablement ...